“Hepatic hilum area priority,liver posterior first”:An optimized strategy in laparoscopic resection for type Ⅲ-Ⅳ hilar cholangiocarcinoma

BACKGROUND In recent years,pure laparoscopic radical surgery for Bismuth-Corlette type Ⅲ and Ⅳ hilar cholangiocarcinoma(HCCA)has been preliminarily explored and applied,but the surgical strategy and safety are still worthy of further improvement and attention.AIM To summarize and share the application experience of the emerging strategy of“hepatic hilum area dissection priority,liver posterior separation first”in pure laparoscopic radical resection for patients with HCCA of Bismuth-Corlette types Ⅲ and IV.METHODS The clinical data and surgical videos of 6 patients with HCCA of Bismuth-Corlette types Ⅲ and Ⅳ who underwent pure laparoscopic radical resection in our department from December 2021 to December 2023 were retrospectively analyzed.RESULTS Among the 6 patients,4 were males and 2 were females.The average age was 62.2±11.0 years,and the median body mass index was 20.7(19.2-24.1)kg/m^(2).The preoperative median total bilirubin was 57.7(16.0-155.7)μmol/L.One patient had Bismuth-Corlette type Ⅲa,4 patients had Bismuth-Corlette type Ⅲb,and 1 patient had Bismuth-Corlette type Ⅳ.All patients successfully underwent pure laparoscopic radical resection following the strategy of“hepatic hilum area dissection priority,liver posterior separation first”.The operation time was 358.3±85.0 minutes,and the intraoperative blood loss volume was 195.0±108.4 mL.None of the patients received blood transfusions during the perioperative period.The median length of stay was 8.3(7.0-10.0)days.Mild bile leakage occurred in 2 patients,and all patients were discharged without serious surgery-related complications.CONCLUSION The emerging strategy of“hepatic hilum area dissection priority,liver posterior separation first”is safe and feasible in pure laparoscopic radical surgery for patients with HCCA of Bismuth-Corlette types Ⅲ and Ⅳ.This strategy is helpful for promoting the modularization and process of pure laparoscopic radical surgery for complicated HCCA,shortens the learning curve,and is worthy of further clinical application.

基于上皮细胞-间充质细胞转分化(EMT)理论的艾灸配合化纤Ⅳ号方对实验大鼠Collagen Type Ⅲ和PDGF干预作用实验研究

目的:基于上皮细胞-间充质细胞转分化(EMT)学说观察化纤Ⅳ号方、艾灸以及二者相配合治疗肺纤维化大鼠Collagen TypeⅢ(Ⅲ-C)和PDGF的变化,探讨其治疗效应及生物学机制。方法:将鼠龄约为6周的SD大鼠随机分为空白组、模型组、化纤Ⅳ号方组、艾灸组、化纤Ⅳ号方与艾灸配合治疗组(简称为"灸药组"),治疗30 d后处死观察其肺组织病理改变,并检测其Collagen TypeⅢ、PDGF的基因和蛋白表达情况。结果:实时荧光定量结果显示:与空白组相比,各组Ⅲ-C和PDGF m RNA表达增高(P<0.05)。与模型组相比,各组的Ⅲ-C和PDGF m RNA表达有明显降低(P<0.01)。而各组中,灸药组疗效最明显,Ⅲ-C和PDGF的表达最低。蛋白免疫印迹法检测结果显示:与模型组相比各组的Ⅲ-C蛋白表达有差异。结论:1艾灸、化纤Ⅳ号方均可减轻博莱霉素诱导肺纤维化大鼠的肺纤维化程度。2艾灸配合化纤Ⅳ号方可减轻博莱霉素诱导肺纤维化大鼠的肺纤维化程度,且其效果优于单用艾灸或单用化纤Ⅳ号方。3艾灸、化纤Ⅳ号方及其二者配合使用不同程度阻抑博莱霉素诱导肺纤维化大鼠肺纤维化进程的效应机制,可能与通过调控其EMT过程中的Ⅲ-C和PDGF表达环节紧密相关。

Serum hyaluronic acid, procollagen type Ⅲ and Ⅳ in histological diagnosis of liver fibrosis

OBJECTIVE: To assess the significance of serum hyaluronic acid (HA), proeollagen type Ⅲ (PCⅢ), collagen type Ⅳ (CⅣ) in the histological diagnosis of liver fibrosis. METHODS: The concentrations of serum HA, PCⅢ, CⅣ in 253 patients with chronic liver diseases were measured by radioimmunoassay. Liver biopsies were performed in all patients at the same time. The liver was pathologically evaluated by a pathologist according to a scoring system. Combined with the results of liver pathological diagnosis, the accuracy of serum HA, PCⅢ, CⅣ in diagnosing patients with hepatic fibrosis (staging≥S_2) or cirrhosis (S_4) was assessed using the receiver operating curve (ROC). RESULTS: The cutoff values of serum HA, PCⅢ and CⅣ for identifying patients with hepatic fibrosis (≥S_2) or cirrhosis (S_4) were determined. The cutoff values of serum HA, PCⅢ and CⅣ for detecting patients with fibrosis (stage≥S_2) were 90μg/L, 90μg/L, 75μg/L, respectively; their sensitivity (Se) was 80.4%, 82%, 63.1%; their specificity (Spe) was 70.2%, 60.8%, 83.8%; their positive predictive values (PPV) were 86.7%, 83.5%, 90.4%; their negative predictive values (NPV) were 59.8%, 58.4%, 48.4%, respectively. The cutoff values for detecting patients with liver cirrhosis were 210μg/L for HA, 96.2% for Se, 85.3% for Spe, 65.4% for PPV, 98.8% for NPV; 150μg/L for PCⅢ, 76.4% for Se, 68.7% for Spe, 40.4% for PPV, 91.3% for NPV; 90μg/L for CⅣ, 80% for Se, 75.8% for Spe, 47.8% for PPV, 93.2% for NPV, respectively. CONCLUSIONS: Serum HA, PCⅢ and CⅣ can be determined for an accurate diagnosis of hepatic fibrosis in various stages. HA is the best for screening liver cirrhosis.

Macroscopic appearance of TypeⅣand giant Type Ⅲ is a high risk for a poor prognosis in pathological stage Ⅱ/Ⅲ advanced gastric cancer with postoperative adjuvant chemotherapy

AIM To evaluate whether a high risk macroscopic appearance(Type Ⅳ and giant Type Ⅲ) is associated with a dismal prognosis after curative surgery, because its prognostic relevance remains elusive in pathological stage Ⅱ/Ⅲ(p Stage Ⅱ/Ⅲ) gastric cancer.METHODS One hundred and seventy-two advanced gastric cancer(defined as pT2 or beyond) patients with p Stage Ⅱ/Ⅲ who underwent curative surgery plus adjuvant S1 chemotherapy were evaluated, and the prognostic relevance of a high-risk macroscopic appearance was examined. RESULTS Advanced gastric cancers with a high-risk macroscopic appearance were retrospectively identified by preoperative recorded images. A high-risk macroscopic appearance showed a significantly worse relapse free survival(RFS)(35.7%) and overall survival(OS)(34%) than an average risk appearance(P = 0.0003 and P < 0.0001, respectively). A high-risk macroscopic appearance was significantly associated with the 13^(th) Japanese Gastric Cancer Association(JGCA) pT(P = 0.01), but not with the 13^(th) JGCA pN. On univariate analysis for RFS and OS, prognostic factors included 13^(th) JGCA p Stage(P < 0.0001)and other clinicopathological factors including macroscopic appearance. A multivariate Cox proportional hazards model for univariate prognostic factors identified highrisk macroscopic appearance(P = 0.036, HR = 2.29 for RFS and P = 0.021, HR = 2.74 for OS) as an independent prognostic indicator. CONCLUSION A high-risk macroscopic appearance was associated with a poor prognosis, and it could be a prognostic factor independent of 13^(th) JGCA stage in p Stage Ⅱ/Ⅲ advanced gastric cancer.

Subtotal gastrectomy combined with chemotherapy: An effective therapy for patients with circumscribed Borrmann type Ⅳ gastric cancer

BACKGROUND Although Borrmann type Ⅳ(B-4) gastric cancer has a higher mortality rate and presents distant metastasis easily, especially peritoneal metastasis, when diagnosed, some B-4 patients were found to have no distant metastasis by preoperative detection and underwent curative surgery, which was defined as circumscribed B-4 in our study. In this study, we focused on the circumscribed B-4 patients without distant metastasis during surgery to identify factors related to prognosis and postoperative peritoneal cavity metastasis(PPCM), which is important for selecting an appropriate therapeutic strategy.AIM To identify factors related to the prognosis and PPCM of B-4 patients.METHODS A total of 117 B-4 patients who underwent gastrectomy between January 2005 and December 2012 were included in this study. Survival analysis was performed using Kaplan–Meier analysis and Cox multivariate models. Pearson correlation analyses were performed to identify the factors related to PPCM. All statistical analyses were performed using SPSS 20.0.RESULTS Lymph node status, gastrectomy type, and postoperative chemotherapy were independent prognostic factors in 117 circumscribed B-4 patients. Subtotal gastrectomy combined with chemotherapy could significantly improve the longterm survival time. Six patients who were diagnosed with pN0 and received the combination therapy had a 3-year survival rate of 100% and a median survival of 77.7 mo. Even for patients with metastatic lymph nodes(n = 13), the combination therapy also increased the 3-year overall survival rate to 57.1%. In addition, positive lymph node status was the only factor(P = 0.005) correlated with PPCM in certain B-4 patients, and chemotherapy was useful for suppressing PPCM in patients with subtotal gastrectomy but not in those with total gastrectomy.CONCLUSION Lymph node status is an independent prognostic factor for circumscribed B-4 patients. In addition, subtotal gastrectomy and postoperative chemotherapy could effectively improve prognosis and even suppress PPCM.

Ⅲ型和Ⅳ型前列腺炎患者前列腺按摩液中锌离子浓度检测和临床价值

目的:探讨前列腺按摩液(EPS)中锌离子浓度对Ⅲ型和Ⅳ型前列腺炎诊疗的意义和参考价值。方法:根据NIH前列腺炎分型标准,将入选的173例研究对象分为ⅢA型(n=65)、ⅢB型(n=69)、Ⅳ型(n=39)前列腺炎,并以35例门诊健康体检、无前列腺炎症状者为对照组,检测4组EPS中锌离子浓度,并分析其与慢性前列腺炎症状评分(CPSI),年龄,EPS中白细胞计数、p H值等指标的相关性。结果:ⅢA型及ⅢB型前列腺炎患者EPS中锌离子浓度[(162.2±10.8)、(171.2±12.0)μg/ml]显著低于Ⅳ型及对照组[(234.6±17.9)、(259.5±14.6)μg/ml),P均<0.05]。EPS中锌离子浓度与疼痛评分、生活质量(QOL)评分、症状严重评分以及CPSI总评分均呈显著负相关(r分别为-0.284、-0.232、-0.270、-0.281,P均<0.01),与排尿症状评分无相关。EPS中锌离子浓度与白细胞计数、年龄无明确相关,与p H值呈负相关(r=-0.208,P<0.01)。结论:Ⅲ型和Ⅳ型前列腺炎患者EPS中锌离子浓度低下可能与疼痛等前列腺炎相关症状有关,EPS中锌离子浓度检测对Ⅲ型和Ⅳ型前列腺炎的诊疗具有潜在参考价值。

血清透明质酸、Ⅲ型前胶原、Ⅳ型胶原及层粘蛋白水平与实验性肝纤维化的关系

目的 :评价血清透明质酸 (HA)、Ⅲ型前胶原 (PCⅢ)、Ⅳ型胶原 (CⅣ)及层粘蛋白 (LN)水平与实验性肝纤维化的关系。方法 :采用半定量计分系统 (SSS)中炎症活动度及纤维化程度计分方案对温阳中药肝之福预防及治疗肝纤维化大鼠实验的病理组织共 73份标本进行半定量计分 ,同时检测血清HA、PCⅢ、CⅣ及LN水平 ,进行Pearson相关性分析。结果 :四项血清肝纤维化指标不论与肝脏炎症活动度还是纤维化程度均呈正相关 (P <0 0 1)。结论 :血清HA、PCⅢ、CⅣ及LN水平可在一定程度上反映肝组织的炎症和纤维化程度 ,联合检测价值较高。

超声内镜和多层螺旋CT对BorrmannⅣ型胃癌术前分期的比较研究

目的对超声内镜(EUS)和多层螺旋CT(MSCT)检查在BorrmannⅣ型胃癌术前分期中的作用进行比较。方法回顾性分析48例BorrmannⅣ型胃癌患者的影像学术前TNM分期,并与术后病理分期进行比较。结果 EUS和MSCT检查对T分期的准确率分别为54.2%和79.2%(P=0.009),分层分析表明MSCT对T3、T4分期的准确率高于EUS(T3:84.6%vs 57.7%,P=0.032;T4:82.4%vs 41.2%,P=0.032)。两者对N分期的准确率,均为56.3%(P=1.000),无明显差异,EUS和MSCT对淋巴转移检查的特异度和灵敏度分别为83.3%/72.2%和66.7%/91.7%。结论 EUS更适合对早期胃癌分期,而已浸润至浆膜层及有远处转移的BorrmannⅣ型胃癌患者,应优先选择MSCT检查进行分期。

血清透明质酸Ⅲ型前胶原Ⅳ型胶原及脯氨酸肽酶对肝组织纤维化诊断的意义

探讨肝病患者血清透明质酸(HA),Ⅲ型前胶原(PCⅢ),Ⅳ型胶原(CⅣ)及脯氨酸肽酶(PLD)水平与肝纤维化程度的关系。用酶联免疫(ELISA)法及生化比色法检测225例各种肝病患者血清中HA、PCⅢ、CⅣ及PLD水平,并与肝活检病理炎症分级和纤维化分期相比较。四项指标与肝组织炎症坏死及纤维化程度均呈显著相关(P<0.05)。HA、PCⅢ及CⅣ与肝纤维化相关性高于炎症,PLD与炎症的相关性高于纤维化。血清学指标与肝组织病理病变程度一致,联合检测肝病患者血清HA、PCⅢ、CⅣ及PLD水平,既可反映肝纤维化严重程度,又能了解肝坏死情况,为临床诊断治疗提供参考。

透明质酸、层粘连蛋白、Ⅲ型前胶原和Ⅳ型胶原血清学指标对肝硬化诊断的价值

目的:评价血清纤维化指标对于诊断肝硬化的应用价值。方法:52例经肝穿刺确诊为慢性乙型肝炎及肝硬化患者,应用放射免疫法检测血清HA(透明质酸)、LN(层粘连蛋白)、PCⅢ(Ⅲ型前胶原)、CⅣ(Ⅳ型胶原)水平。结果:肝脏病理炎症及纤维化分级与血清HA、LN、PCⅢ、CⅣ水平有显著相关性,组间对比部分有统计学意义,炎症分级组较为明显。结论:检测血清HA、LN、PCⅢ、CⅣ水平对于判断肝脏炎症及纤维化程度有一定价值和意义。

血清肝纤维化HA、Ⅳ-C、PCⅢ和LN联合检测在布加综合征导致的肝纤维化诊断中的价值

目的:探讨血清透明质酸(hyaluronic acid,HA)、Ⅳ型胶原(type Ⅳ collagen,Ⅳ-C)、Ⅲ型前胶原肽(type Ⅲ procollagen,PCⅢ)、层黏连蛋白(laminin,LN)检测在布加综合征(budd-chiari syndrome,BCS)导致肝纤维化诊断的价值.方法:应用化学发光法分别检测我院介入科2004-03/2012-06收治的61例BCS患者(研究组)及60例健康者(对照组)血清HA、Ⅳ-C、PCⅢ、LN含量,并进行统计学分析.结果:BCS患者血清HA、Ⅳ-C、PCⅢ、LN含量均高于对照组,差异具有统计学意义,分别为t=6.879,P<0.05;t=7.071,P<0.05;t=5.753,P<0.05;t=6.330,P<0.05.研究组进行组间比较,血清HA、Ⅳ-C、PCⅢ、LN含量差异无统计学意义(P>0.05).结论:血清HA、Ⅳ-C、PCⅢ、LN作为检测肝纤维化灵敏指标,联合检测对BCS导致肝纤维化的诊断和临床治疗具有重要意义.

血清HA、PCⅢ和PCⅣ联合检测评估肝纤维化的临床病理价值

目的 寻求反映肝纤维化的无创性检查。方法 联合检测 48例各种类型的肝病血清Ⅲ前胶原 (serumtypeⅢ procollagen ,PCⅢ )、透明质酸 (hyaluronateacid ,HA)、血清Ⅳ型胶原 (serumtypeⅣ procogen ,PCⅣ ) ,并与其肝组织病变对照研究。结果 显示血清HA、PCⅢ和PCⅣ水平在慢性肝炎轻度、中度、重度和重型肝炎呈现进行性升高。血清HA、PCⅢ和PCⅣ随肝组织炎症活动指数和肝组织纤维化程度加重而升高。结论 若能去除炎症因素的影响 。

肝病患者血清中TIMP-1与HA、PCⅢ、CⅣ、LN水平的相关性

目的了解肝病患者血清中基质金属蛋白酶组织抑制物-1(TIMP-1)与透明质酸(HA)、Ⅲ型前胶原(PCⅢ)、Ⅳ型胶原(CⅣ)和层粘连蛋白(LN)的相互关系及临床意义。方法425例肝病患者和110例正常对照者采用双抗体夹心酶联免疫吸附方法(ELISA)测定血清TIMP-1,放射免疫分析法测定HA、PCⅢ、CⅣ和LN和全自动酶法测定血清总胆汁酸(TBA)、丙氨酸氨基转移酶(ALT)。结果与健康正常人对照比较,肝病患者五项指标均有不同程度的升高,除慢性肝炎轻度组CⅣ含量水平与对照组无统计学意义外,其余各组均与对照组有显著性差异(P<0.01)。其中唯有TIMP-1血清含量水平从急性肝炎至肝硬化依次进行性升高,慢性肝炎轻度组与急性肝炎组相比,t=2.603,P<0.01。血清TIMP-1与HA、PCⅢ、CⅣ和LN呈显著正相关(P<0.01),与TBA、ALT呈正相关(P<0.05),并随肝脏病损纤维化程度加重而检出阳性率逐渐增高(P<0.005)。结论五项指标均可不同程度的反映肝脏的纤维化程度,其中以血清TIMP-1更为可靠、有效。

Borrmann Ⅳ型胃癌18例误诊分析

目的分析BorrmannⅣ型胃癌的临床特点、误诊原因及防治策略。方法回顾性分析1996年1月-2013年1月南昌解放军第94医院肿瘤科经病理学证实的BorrmannⅣ型胃癌误诊患者18例临床资料,并复习相关文献。结果 BorrmannⅣ型胃癌患者18例中男7例,女11例,年龄30~71岁;病程1周~3个月,均曾接受1~2次胃镜检查。误诊为慢性胃炎7例,消化性溃疡6例,结核性腹膜炎2例,卵巢癌3例。18例经上消化道造影或腹部CT检查和体检提示有异常,再次行胃镜检查或手术而确诊,其中中分化腺癌1例,低分化腺癌6例,黏液腺癌2例,印戒细胞癌6例,未分化癌3例。接受胃癌姑息性手术9例,行卵巢转移癌姑息性手术2例,行全身化疗和腹腔灌注化疗12例。最长生存期为23个月,9例生存期不超过1年。结论胃镜联合上消化道造影、腹部CT和超声内镜检查可提高BorrmannⅣ型胃癌的检出率,以手术为主的综合治疗可改善患者生存期。

血清HA、PCⅢ、Ⅳ-C和LN水平对诊断肝纤维化的临床意义

为探讨血清HA、PCⅢ、Ⅳ -C和LN水平对诊断肝纤维化的临床价值 ,对 180例慢性肝病患者分别采用RIA测定血清HA、PCⅢ、Ⅳ -C和LN水平。结果表明 ,血清HA、PCⅢ、Ⅳ -C和LN水平在慢性肝炎中度、重度及肝硬化患者明显高于对照组 (P <0 .0 5 ) ,且随着肝脏炎症和纤维化程度的加重而升高。结论是血清HA、PCⅢ、Ⅳ -C和LN水平可反映肝纤维化程度 ,四项联合检测是判断肝纤维化和早期肝硬化的无创伤性的、相对灵敏的指标。

超声定位下凿洞式深挖活检对Borrmann Ⅳ型胃癌诊断价值的探讨

目的:探讨超声内镜定位下凿洞式深挖活检对BorrmannⅣ型胃癌诊断的价值。方法:回顾性分析病理确诊的53例BorrmannⅣ型胃癌的临床资料,比较常规活检及超声内镜定位下凿洞式深挖活检对BorrmannⅣ型胃癌的诊断结果。结果:常规胃镜首次活检诊断BorrmannⅣ型胃癌阳性率30.2%(16/53),活检阴性患者多次重复活检阳性率13.5%(5/37),常规内镜活检总阳性率为39.6%(21/53)。46例BorrmannⅣ型胃癌患者行超声内镜检查,诊断与病理符合率为95.5%(44/46)。21例多次活检阴性患者行超声内镜定位下凿洞式深挖活检,术后标本送病理检查阳性率61.9%(13/21)。仅2例患者活检后创面少量渗血,所有患者术后观察无出血、穿孔等并发症发生。结论:超声内镜定位下凿洞式深挖活检显著提高BorrmannⅣ型胃癌临床内镜活检阳性率,为BorrmannⅣ型胃癌的诊断提供了更有效的病理确诊依据。该操作安全性高,费用少,值得临床推广。

肺纤维化患者血清Ⅲ型前胶原、Ⅳ型胶原及脯氨酸肽酶含量的改变

目的 探讨肺纤维化患者血清Ⅲ型前胶原 (PCⅢ )、Ⅳ型胶原 (CⅣ )及脯氨酸肽酶 (PLD)的含量变化及临床意义。方法 对 2 5例肺纤维化患者和 2 0例健康人采用放射免疫分析法检测血清中PCⅢ及CⅣ的含量 ;用比色法检测血清中PLD含量。结果 肺纤维化患者血清中PCⅢ及CⅣ含量明显增高 ,同时PLD含量亦增加 ,与健康对照组比较 ,差异有显著性 (P <0 .0 1) ,且三者之间呈明显正相关 (P <0 .0 5或 <0 .0 1)。结论 肺纤维化患者血清PCⅢ、CⅣ及PLD的水平可作为反映肺纤维化改变的参考指标。

解剖锁定钢板植骨与不植骨治疗Sanders Ⅲ、Ⅳ型跟骨骨折疗效比较

目的 对比解剖锁定钢板内固定后植骨与不植骨治疗SandersⅢ、Ⅳ型跟骨骨折的临床疗效.方法 将61例SandersⅢ、Ⅳ型跟骨骨折患者按随机数字表法分为两组：A组（31例）采用切开复位、解剖锁定钢板固定＋自体髂骨植骨治疗,B组（30例）采取切开复位解剖锁定钢板固定不植骨治疗.对手术前后各项指标进行比较.结果 手术时间：A组80 min±7.6 min,B组63 min±3.6 min,差异有统计学意义（P＜0.05）.61例均获随访,时间12～23个月.骨折愈合时间：A组9～15（ 11.5±1.1）周,B组10～15（ 11.9±1.4）周,差异无统计学意义（P＞0.05）.术后1年两组Bhler角、Gissane角、跟骨宽度比较差异均无统计学意义（P＞0.05）;术后1年两组功能评分差异无统计学意义（P＞0.05）.A组有6例取骨区不适,B组因未取骨而无不适,差异有统计学意义（P＜0.05）.结论 切开复位解剖锁定钢板固定后植骨与不植骨治疗跟骨骨折临床疗效相当,但取髂骨植骨明显延长手术时间,增加取骨区手术创伤,术后可能遗留取骨区不适,故解剖锁定钢板固定不植骨治疗SandersⅢ、Ⅳ型跟骨骨折优于植骨治疗.

严重急性呼吸综合征患者血清Ⅲ型前胶原、Ⅳ型胶原含量测定及临床意义

目的 测定严重急性呼吸综合征 (SARS)患者血清Ⅲ型前胶原、Ⅳ型胶原含量变化 ,探讨其作为反映早期纤维化肺指标的价值。方法 用放射免疫法检测 66例SARS患者血清Ⅲ型前胶原、Ⅳ型胶原含量 ,与正常对照组比较。结果 血清Ⅲ型前胶原含量两组间比较无显著性差异(P >0 0 5)。SARS组恢复期Ⅳ型胶原含量明显高于SARS组进展期及对照组 (P <0 0 1)。X线胸片病灶吸收缓慢者Ⅳ型胶原含量较高。结论 部分SARS患者体内血清Ⅳ型胶原含量增高 ,与肺部病灶吸收和纤维化程度有关。

Kasai术式在Ⅲ、Ⅳ型肝门胆管癌切除术中应用

目的探讨Kasai术式在Ⅲ、Ⅳ型肝门胆管癌切除中应用的安全性和实用性。方法 2008年4月至2011年12月间,对7例Ⅲ、Ⅳ型肝门胆管癌行Kasai术式进行手术。结果 3例胆漏,其中2例量少,引流5～7天后停止,1例较多,每日约100～200 ml,4周后自行愈合。1例切口感染,2例出现腹水,给予营养支持、保肝、利尿等治疗后痊愈。结论选择性Kasai胆肠内引流术式应用于Ⅲ、Ⅳ型肝门胆管癌切除中方法简易、安全、实用。